Drug Approval | December 03, 2025
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Presbyopia, the age-related loss of near vision, could soon be treated successfully
GV20 received an upfront payment and is eligible for additional milestone payments
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Subscribe To Our Newsletter & Stay Updated
